Compare LEGH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEGH | EYPT |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | United States | United States |
| Employees | N/A | 214 |
| Industry | Homebuilding | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.6M | 312.1M |
| IPO Year | 2018 | 2005 |
| Metric | LEGH | EYPT |
|---|---|---|
| Price | $29.17 | $3.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $25.00 | ★ $31.80 |
| AVG Volume (30 Days) | 62.6K | ★ 3.3M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $164,567,000.00 | $7,539,000.00 |
| Revenue This Year | $11.90 | N/A |
| Revenue Next Year | $6.58 | $3,115.57 |
| P/E Ratio | $20.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $18.29 | $3.27 |
| 52 Week High | $31.34 | $19.11 |
| Indicator | LEGH | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 59.22 | 30.01 |
| Support Level | $28.00 | N/A |
| Resistance Level | $30.92 | $14.72 |
| Average True Range (ATR) | 0.90 | 0.31 |
| MACD | 0.12 | 0.20 |
| Stochastic Oscillator | 76.11 | 10.30 |
Legacy Housing Corp builds, sells, and finances manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores, and are also sold directly to manufactured home communities. The Company manufactures and provides for the transport of manufactured homes, provides wholesale financing to dealers and mobile home parks, provides retail financing to consumers, and is involved in financing and developing new manufactured home communities. The Company manufactures its mobile homes at plants in Fort Worth, Texas; Commerce, Texas; and Eatonton, Georgia. The Company also sells homes directly to consumers, through its own retail stores, and to dealers and mobile home parks.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.